ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET

ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth  Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by year-end 2023

ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

Dare Bioscience

Oncolytics Biotech, Inc.

ReTo Eco-Solutions

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $4 Right Now

ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million.  The preliminary results represent the Company's highest quarterly revenue since its inception.

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

2021 was a difficult time to be an ADMA shareholder with dilution having a significant impact on ADMA's stock price.

ADMA Biologics: 2021 Was Tough

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023

ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a 6-month term stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one right (the “Right”) for each outstanding share of common stock. The record date for the dividend distribution is December 30, 2021. The Rights Plan will expire, without any further action required to be taken by ADMA's Board of Directors, on June 15, 2022.

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options

Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin

ADMA Biologics Provides Update on Global Intellectual Property Portfolio

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones.

ADMA Biologics: Turning A Corner

New Oriental Education & Technology Group

Stran & Co

Check these penny stocks out for your watchlist The post Are These Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks on Your Watchlist Right Now?

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Cyndi Tolman, ADMA's Senior Vice President of Plasma Services, has been elected to serve on the PPTA Source Board of Directors (“PPTA Source Board”) for the 2022 to 2024 election term.

ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors

ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction

ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the continued commercial ramp-up of ADMA's intravenous immune globulin (IVIG) product portfolio and the sale of intermediate fractions.

ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call Transcript

Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020

ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

Preview: ADMA Biologics's Earnings

Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET

ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021

ADMA has been trading in a downward trajectory over the past few years. ADMA's stock price has taken a beating from several equity offerings as the business continues to invest in the future.

ADMA: Insiders Showing Their Cards

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adma Biologics (ADMA) Report Negative Q3 Earnings? What You Should Know

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 7.5 million shares of common stock. The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Borqs Technologies

Powerbridge Technologies Co Ltd

Penny stocks are seeing heightened momentum, which companies are you watching? The post Best Penny Stocks to Watch as The Market Turns Bullish appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch as The Market Turns Bullish

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference. The abstract and poster presentation detailed the use of ASCENIV TM, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a 70-year-old African American male with a history of bronchiectasis who presented with severe respiratory viral disease and confirmed COVID-19 infection.

ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, resulting in gross proceeds of approximately $50 million before deducting underwriting discounts and commissions and other estimated offering expenses.

News for ADMA Biologics Stock (ADMA)